Former Biovail CEO Quits Valeant

BMI View: We believe there is a dichotomy in the strategies employed by pharmaceuticals companies. Traditionalists are refocusing on original research and development (R&D) and concentrating on their core competencies, while the other approach is diversification into low-risk, immediate-return ventures though product acquisitions and licensing agreements. Although we believe a synergy of the two strategies could be highly successful, we expect that drugmakers investing to fortify internal R&D will outperform in the long

To read the full article, please choose one of the following options: